Oxford–AstraZeneca

Oxford–AstraZeneca
Name	Oxford–AstraZeneca
Type	Vaccine
Target	SARS-CoV-2
Vaccine type	Viral vector
Tradename	Vaxzevria, Covishield
Manufacturer	AstraZeneca, University of Oxford, Serum Institute of India
Diseases	COVID-19
Routes of administration	Intramuscular injection
Atc prefix	J07
Legal status	* WHO: Emergency Use Listing * EMA: Conditional * MHRA: Authorized

Oxford–AstraZeneca. The Oxford–AstraZeneca COVID-19 vaccine, also known as Vaxzevria and Covishield, is a viral vector vaccine for the prevention of COVID-19. It was developed through a landmark collaboration between the University of Oxford and the British-Swedish multinational AstraZeneca, with key contributions from the Jenner Institute and the Oxford Vaccine Group. The vaccine became a cornerstone of the global response to the COVID-19 pandemic, authorized for use in over 180 countries and distributed widely through initiatives like COVAX.

Development and technology

The vaccine's development was led by a team at the University of Oxford under Professors Sarah Gilbert, Andrew Pollard, and Teresa Lambe. The core technology utilizes a modified, replication-deficient chimpanzee adenovirus vector, known as ChAdOx1, which was engineered to deliver the genetic sequence for the SARS-CoV-2 spike protein. This approach built upon prior research for vaccines against diseases like Middle East respiratory syndrome and Ebola virus disease. The partnership with AstraZeneca was crucial for scaling up manufacturing and committing to non-profit distribution during the pandemic, a stance supported by funding from organizations like the Coalition for Epidemic Preparedness Innovations and the Bill & Melinda Gates Foundation.

Clinical trials and efficacy

Large-scale clinical trials were conducted internationally, including pivotal Phase III studies in the United Kingdom, Brazil, and South Africa. The primary regimen tested involved two doses administered four to twelve weeks apart. Interim analysis published in The Lancet in December 2020 showed an average efficacy of approximately 70% against symptomatic COVID-19, with higher protection observed with a longer interval between doses. Subsequent real-world data from Public Health England and Health Canada demonstrated strong effectiveness, particularly against severe disease, hospitalization, and death caused by variants like the Alpha variant and the Delta variant.

Manufacturing and distribution

To meet global demand, a complex international manufacturing network was established. AstraZeneca subcontracted production to numerous partners, including the Serum Institute of India (which produced the vaccine as Covishield), SK Bioscience in South Korea, and the Halix plant in the Netherlands. The vaccine's simpler storage requirements, compatible with standard refrigerator temperatures, made it logistically advantageous for distribution in low- and middle-income countries. It formed the backbone of supplies for the COVAX facility, co-led by the World Health Organization, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations.

Authorizations and usage

The vaccine received its first emergency authorization in December 2020 from the Medicines and Healthcare products Regulatory Agency in the United Kingdom. It subsequently received Conditional marketing authorization from the European Medicines Agency and was added to the World Health Organization's WHO Emergency Use Listing. While authorized by Health Canada and many other nations, it did not receive an Emergency Use Authorization from the U.S. Food and Drug Administration. By mid-2021, it was the most widely administered vaccine globally, with billions of doses delivered.

Controversies and side effects

The vaccine's rollout was accompanied by several challenges. In early 2021, numerous European Union member states temporarily suspended its use following reports of rare blood clotting events, termed Thrombosis with thrombocytopenia syndrome, which were later confirmed by investigations from the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency. Supply disputes also arose between the European Commission and AstraZeneca over contractual delivery schedules. Furthermore, concerns were raised about its reduced efficacy against the Beta variant and the Omicron variant of SARS-CoV-2.

Impact and legacy

The Oxford–AstraZeneca vaccine had a profound impact on the course of the COVID-19 pandemic, particularly in preventing severe outcomes and deaths worldwide during 2021. Its affordable cost and ease of storage allowed for equitable access, saving an estimated millions of lives according to modeling by the World Health Organization. The partnership model between academia and industry, along with the rapid large-scale deployment of a novel viral vector platform, set important precedents for future vaccine development and global health security. Its role remains a central case study in the pandemic response.

Category:COVID-19 vaccines Category:AstraZeneca Category:University of Oxford